AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31302768 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: IANB and buccal infiltration (BI) of 4% articaine
Number of subjects: 90
Study 31302768 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: IANB + BI and intraseptal injection of articaine
Number of subjects: 90
Study 29703998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT) administration
Number of subjects: 58
Study 29703998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) administration
Number of subjects: 58
Study 28370178 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma (6 g containing 2% curcumin)
Number of subjects: 18
Study 28370178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26438237 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term fasting (STF) 24 hours before and after chemotherapy
Number of subjects: 13
Study 26438237 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-STF)
Number of subjects: 13
Study 23504523 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in physical activity score by 23 units
Number of subjects: 0
Study 23504523 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in BMI by 1.9 units
Number of subjects: 0
Study 21722581 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 100
Study 21722581 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 100
Study 21722581 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) for ≥ 48 days
Number of subjects: 100
Study 21722581 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) for <48 days
Number of subjects: 100
Study 19808351 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial B-type natriuretic peptide testing (at 3, 6, 9, and 12 hours then daily)
Number of subjects: 447
Study 19808351 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 447
Study 19808351 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial B-type natriuretic peptide testing
Number of subjects: 447
Study 17584566 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 200
Study 17584566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 15386625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor tractography and voxel-based analysis in ALS patients
Number of subjects: 7
Study 15386625 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 age- and sex-matched volunteers)
Number of subjects: 7
Study 11435883 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (240 ml, 3 times daily for 7 days)
Number of subjects: 10
Study 11435883 — intervention group
Group type: COMPARATOR
Intervention: Control (tap water, 240 ml, 3 times daily for 7 days)
Number of subjects: 10
Study 9682700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1439
Study 9682700 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1439
Study 9682700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with early worsening
Number of subjects: 1439
Study 9682700 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin A1c level at screening
Number of subjects: 1439
Study 9682700 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of hemoglobin A1c during the first 6 months
Number of subjects: 1439
Study 9682700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment initiation
Number of subjects: 1439
Study 8026287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acids (HMUFA) diet
Number of subjects: 12
Study 8026287 — intervention group
Group type: COMPARATOR
Intervention: High-complex carbohydrates (high-CHO) diet
Number of subjects: 12
Study 28801967 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental retreatment with subcutaneous bortezomib plus dexamethasone (VD)
Number of subjects: 80
Study 28801967 — intervention group
Group type: COMPARATOR
Intervention: Standard VD retreatment
Number of subjects: 80
Study 26748537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary placement
Number of subjects: 808
Study 26748537 — intervention group
Group type: COMPARATOR
Intervention: Control (no pessary)
Number of subjects: 808
Study 24345356 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual with smoking-cessation treatment (weekly individual smoking cessation counseling and extended-release bupropion 300 mg/d during weeks 1-10, nicotine inhaler and contingency management for smoking abstinence during weeks 4-10)
Number of subjects: 538
Study 24345356 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 538
Study 24345356 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual with smoking-cessation treatment
Number of subjects: 538
Study 23027228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness induction
Number of subjects: 32
Study 23027228 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 19954496 — intervention group
Group type: EXPERIMENTAL
Intervention: Football group (FG)
Number of subjects: 53
Study 19954496 — intervention group
Group type: EXPERIMENTAL
Intervention: Running group (RG)
Number of subjects: 53
Study 19954496 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 53
Study 19894661 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 1966
Study 16802260 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized procedure with five brief contacts
Number of subjects: 0
Study 16802260 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 12492746 — intervention group
Group type: EXPERIMENTAL
Intervention: Forlax (10 g)
Number of subjects: 0
Study 12492746 — intervention group
Group type: EXPERIMENTAL
Intervention: Forlax (20 g)
Number of subjects: 0
Study 12492746 — intervention group
Group type: EXPERIMENTAL
Intervention: Transipeg (5.9 g)
Number of subjects: 0
Study 12492746 — intervention group
Group type: EXPERIMENTAL
Intervention: Transipeg (11.8 g)
Number of subjects: 0
Study 12492746 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10844354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total knee arthroplasty
Number of subjects: 96
Study 10844354 — intervention group
Group type: COMPARATOR
Intervention: Uncemented total knee arthroplasty
Number of subjects: 96
Study 10844354 — intervention group
Group type: COMPARATOR
Intervention: Noncemented total knee arthroplasty
Number of subjects: 96
Study 9337835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of gas mixtures with varying fractional inspired oxygen concentration (FiO2) from 0.1 to 1.0
Number of subjects: 16
Study 9337835 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of gas mixtures with FiO2 of 0.1
Number of subjects: 16
Study 8449125 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamin A 30,000 IU/day, vitamin C 1 g/day, vitamin E 70 mg/day)
Number of subjects: 209
Study 8449125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (20 g/day)
Number of subjects: 209
Study 8449125 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 209
Study 2869676 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 to 160 mg 3 times a day)
Number of subjects: 17
Study 2869676 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 120 mg 3 times a day)
Number of subjects: 17
Study 29864732 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered mindfulness-based cognitive therapy (MBCT-T)
Number of subjects: 144
Study 29864732 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 144
Study 27825738 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAP) alone
Number of subjects: 694
Study 27825738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) + Primaquine 0.20mg/kg
Number of subjects: 694
Study 27825738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) + Primaquine 0.40mg/kg
Number of subjects: 694
Study 27825738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) + Primaquine 0.75mg/kg
Number of subjects: 694
Study 25525171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus
Number of subjects: 6
Study 25525171 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 6
Study 22483737 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 0
Study 22483737 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for delineation of the postoperative CTV and normal tissues
Number of subjects: 0
Study 20531202 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1%
Number of subjects: 85
Study 20531202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1%
Number of subjects: 85
Study 20531202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both olopatadine and fluorometholone
Number of subjects: 85
Study 18803955 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 47.0 mg/d
Number of subjects: 153
Study 18803955 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8.4 mg/d
Number of subjects: 153
Study 18803955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in drug regimen)
Number of subjects: 153
Study 16169302 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg nicotine enema
Number of subjects: 48
Study 16169302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine therapy
Number of subjects: 48
Study 16169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 48
Study 11974560 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA 0.625 mg-5.0 mg daily for 13 treatment cycles (28 days each)
Number of subjects: 85
Study 11974560 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 2.5 mg daily for 13 treatment cycles (28 days each)
Number of subjects: 85
Study 11974560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CEE/MPA and Tibolone
Number of subjects: 85
Study 10482696 — intervention group
Group type: EXPERIMENTAL
Intervention: Superselective intra-arterial chemotherapy
Number of subjects: 386
Study 10482696 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic intravenous chemotherapy
Number of subjects: 386
Study 10482696 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 386
Study 8651435 — intervention group
Group type: EXPERIMENTAL
Intervention: Minisston
Number of subjects: 179
Study 8651435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravistat 125
Number of subjects: 179
Study 8651435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigevidon
Number of subjects: 179
Study 8651435 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteovin
Number of subjects: 179
Study 2300106 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity anticoagulation (prothrombin-time ratio, 1.5; INR, 2.65)
Number of subjects: 258
Study 2300106 — intervention group
Group type: COMPARATOR
Intervention: High intensity anticoagulation (prothrombin-time ratio, 2.5; INR, 9)
Number of subjects: 258
Study 6163166 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-globulin/histamine complex by subcutaneous injection
Number of subjects: 138
Study 6163166 — intervention group
Group type: EXPERIMENTAL
Intervention: active treatment (gamma-globulin/histamine complex)
Number of subjects: 138
Study 6163166 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 138
Study 31881879 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy dose TUS combined with a rehabilitation program
Number of subjects: 66
Study 31881879 — intervention group
Group type: COMPARATOR
Intervention: Placebo TUS combined with a rehabilitation program
Number of subjects: 66
Study 28195933 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A lenses
Number of subjects: 282
Study 28195933 — intervention group
Group type: EXPERIMENTAL
Intervention: balafilcon A lenses
Number of subjects: 282
Study 28195933 — intervention group
Group type: EXPERIMENTAL
Intervention: comfilcon A lenses
Number of subjects: 282
Study 26553690 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA‐TT vaccine
Number of subjects: 0
Study 24055241 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4509
Study 21324450 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Number of subjects: 240
Study 21324450 — intervention group
Group type: COMPARATOR
Intervention: Day 5 embryo transfer
Number of subjects: 240
Study 19189904 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate listing for liver transplantation
Number of subjects: 120
Study 19189904 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 17426157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 97
Study 15290413 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed hydroxyethyl starch (HES) infused at 37.1 degrees +/‐ 1.5 degrees C
Number of subjects: 20
Study 15290413 — intervention group
Group type: COMPARATOR
Intervention: Control group (room temperature HES) infused at 34.8 degrees +/‐ 2.2 degrees C
Number of subjects: 20
Study 11738336 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of levofloxacin 500 mg once daily
Number of subjects: 532
Study 11738336 — intervention group
Group type: COMPARATOR
Intervention: 7-day course of levofloxacin 500 mg once daily
Number of subjects: 532
Study 9463638 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (selective AT1 receptor antagonist)
Number of subjects: 0
Study 9463638 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II
Number of subjects: 0
Study 9463638 — intervention group
Group type: COMPARATOR
Intervention: Sodium depletion
Number of subjects: 0
Study 8505747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetard 300 mg
Number of subjects: 45
Study 8505747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetard 100 mg
Number of subjects: 45
Study 8505747 — intervention group
Group type: EXPERIMENTAL
Intervention: Platet 100 mg
Number of subjects: 45
Study 3691010 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 5‐mg tablets (Treatment A)
Number of subjects: 0
Study 3691010 — intervention group
Group type: EXPERIMENTAL
Intervention: One 10‐mg tablet (Treatment B)
Number of subjects: 0
Study 3691010 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of a 1‐mg/mL suspension (Treatment C)
Number of subjects: 0
Study 3691010 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of a 1‐mg/mL aqueous reference solution (Treatment D)
Number of subjects: 0
Study 3691010 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Treatment A and Treatment D
Number of subjects: 0
Study 3691010 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean elimination half‐life
Number of subjects: 0
Study 3691010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence of dosage forms
Number of subjects: 0
Study 30955362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer worn on the hip with visible step count and daily recording
Number of subjects: 78
Study 30955362 — intervention group
Group type: COMPARATOR
Intervention: Pedometer fixed shut worn on the hip with estimated distances recorded
Number of subjects: 78
Study 28820322 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 13
Study 28820322 — intervention group
Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 13
Study 26159207 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 16
Study 26159207 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling technique
Number of subjects: 16
Study 26159207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 23926679 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatic cord seal-up injection (lidocaine, gentamicin or Amikacin, dexamethasone), qd or bid, for 2 courses of 5 days each, with an interval of 3 to 5 days.
Number of subjects: 120
Study 23926679 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment (intravenous drip of penicillin, qd; intramuscular injection of Streptomycin, bid; oral SMZCo, bid, with initial dose doubled).
Number of subjects: 120
Study 21757663 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 608
Study 21757663 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 608
Study 21757663 — intervention group
Group type: COMPARATOR
Intervention: Japanese population
Number of subjects: 608
Study 21757663 — intervention group
Group type: COMPARATOR
Intervention: Multivariable-adjusted IMT
Number of subjects: 608
Study 19688352 — intervention group
Group type: EXPERIMENTAL
Intervention: NuCore Injectable Nucleus hydrogel
Number of subjects: 14
Study 16430322 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping intervention
Number of subjects: 181
Study 16430322 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic counseling
Number of subjects: 181
Study 16430322 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive perception of family's finances
Number of subjects: 181
Study 16430322 — intervention group
Group type: EXPERIMENTAL
Intervention: Less emotional distress
Number of subjects: 181
Study 15387802 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Number of subjects: 44
Study 15387802 — intervention group
Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 44
Study 15387802 — intervention group
Group type: COMPARATOR
Intervention: Combination of eccentric exercises and night splint
Number of subjects: 44
Study 11212044 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil iv followed by a continuous infusion of 0.25 to 0.50 microg x kg(‐1) x min(‐1)
Number of subjects: 30
Study 11212044 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside iv
Number of subjects: 30
Study 11212044 — intervention group
Group type: COMPARATOR
Intervention: Esmolol iv combined with alfentanil iv
Number of subjects: 30
Study 9771298 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms kg‐1)
Number of subjects: 28
Study 9771298 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine (1 mg kg‐1)
Number of subjects: 28
Study 8314135 — intervention group
Group type: EXPERIMENTAL
Intervention: LLETZ
Number of subjects: 375
Study 8314135 — intervention group
Group type: COMPARATOR
Intervention: Laser ablation
Number of subjects: 375
Study 3353831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression stocking applied to the left limb
Number of subjects: 26
Study 3353831 — intervention group
Group type: COMPARATOR
Intervention: Control (right leg and upper limb without compression)
Number of subjects: 26
Study 30370613 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 665
Study 30370613 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plus bupropion SR
Number of subjects: 665
Study 30370613 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR plus mirtazapine
Number of subjects: 665
Study 30370613 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 665
Study 28235621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CAP (2 mg/d; L-CAP, n = 27)
Number of subjects: 77
Study 28235621 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CAP (4 mg/d; H-CAP, n = 22)
Number of subjects: 77
Study 28235621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch; PLA, n = 28)
Number of subjects: 77
Study 25963985 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g GSR‐PAS twice daily
Number of subjects: 0
Study 25963985 — intervention group
Group type: COMPARATOR
Intervention: 8 g GSR‐PAS once daily
Number of subjects: 0
Study 25963985 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT1∗14 and NAT1∗3 alleles
Number of subjects: 0
Study 25963985 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT1∗10 allele
Number of subjects: 0
Study 25963985 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT1 and NAT2 genotypes
Number of subjects: 0
Study 23433101 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg with reduced-dose cyclosporine
Number of subjects: 721
Study 23433101 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine
Number of subjects: 721
Study 21615449 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment for 15 months
Number of subjects: 8
Study 21615449 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment in mice with EAE
Number of subjects: 8
Study 21615449 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (mice)
Number of subjects: 8
Study 19062230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol and ipratropium with warmed humidified oxygen
Number of subjects: 60
Study 19062230 — intervention group
Group type: COMPARATOR
Intervention: Nebulized albuterol and ipratropium with humidified oxygen at room temperature
Number of subjects: 60
Study 19062230 — intervention group
Group type: COMPARATOR
Intervention: Nebulized albuterol with warmed humidified oxygen
Number of subjects: 60
Study 19062230 — intervention group
Group type: COMPARATOR
Intervention: Nebulized albuterol with humidified oxygen at room temperature
Number of subjects: 60
Study 16684985 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care management (n = 84)
Number of subjects: 153
Study 16684985 — intervention group
Group type: COMPARATOR
Intervention: Augmented usual care (n = 69)
Number of subjects: 153
Study 14762410 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT display for grading of diabetic retinopathy
Number of subjects: 49
Study 14762410 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT display for grading of diabetic retinopathy
Number of subjects: 49